ITHS Scholar Awarded R21 to Study C. difficile Therapy
ITHS Rising Star Dr. Kirk Hevener was recently awarded an NIH Exploratory/Developmental Research Grant Award (R21) to investigate the bacterial enzyme FabK as a novel, druggable target for selective therapy of Clostridium difficile infections....